Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia

Bookmark and Share
Published: 15 Jun 2019
Views: 414
Rating:
Save
Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

Dr Paolo Ghia presents results at the 2019 European Hematology Association (EHA) Annual Meeting from the ASCEND study.

Patients with relapsed or refractory chronic lymphocytic leukaemia were randomised to receive either acalabrutinib or the investigator choice of rituximab plus idelalisib (IdR) with acalabrutinib showing a much improved PFS and safety profile.